Company profile: Cellenkos
1.1 - Company Overview
Company description
- Provider of clinical-stage allogeneic cord blood regulatory T cell therapeutics for autoimmune and inflammatory disorders, enabled by the proprietary CRANE platform for cell enrichment and differentiation and in-house cGMP manufacturing. Pipeline includes CK0801 for bone marrow failure syndromes, CK0802 for COVID-19 ARDS, and CK0804 for myelofibrosis.
Products and services
- CRANE® Platform: A proprietary cell enrichment and differentiation system that architects disease-specific allogeneic Treg products for treating autoimmune and inflammatory disorders
- CGMP Manufacturing: An in-house, cGMP-compliant infrastructure that produces, stores, and distributes Treg products to support clinical programs in autoimmune and inflammatory disorders
- CORD BLOOD REGULATORY T CELL THERAPEUTICS: Allogeneic therapeutic products employing regulatory T cells derived from umbilical cord blood to treat inflammatory diseases and autoimmune disorders with disease-specific Treg assemblies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cellenkos
Promedior
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapeutics for inflammatory and fibrotic diseases, supported by a novel drug discovery platform to regulate monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Promedior company profile →
Pliant Therapeutics
HQ: United States
Website
- Description: Provider of integrin-targeted therapies, including bexotegrast (PLN-74809) for IPF and PSC (oral dual αvβ6/αvβ1 inhibitor), PLN-1474 for MASH (αvβ1 inhibitor for late-stage liver fibrosis), PLN-101095 for oncology (targets αvβ8-mediated TGF-β activation to increase sensitivity to checkpoint inhibition therapies), and PLN-101325 for muscular dystrophy (α7β1 integrin activating antibody).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pliant Therapeutics company profile →
Statera Biopharma
HQ: United States
Website
- Description: Provider of biotechnology research services and immune-restorative drug development, advancing STAT-201 for pediatric Crohn's, STAT-205 for acute and post-acute COVID-19, STAT-401 as an adjunct for pancreatic cancer, the AIMS platform targeting complex pathways and toll-like receptors, and Entolimod, a TLR5 agonist for radio-mitigation in cancer patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Statera Biopharma company profile →
Alladapt
HQ: United States
Website
- Description: Provider of prescription therapeutics targeting food allergy; a privately held biopharmaceutical company focused on developing such treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alladapt company profile →
Sitryx
HQ: United Kingdom
Website
- Description: Provider of cell metabolism–targeted, first-in-class, disease-modifying therapeutics in immuno-oncology and immuno-inflammation. Pipeline includes SYX-5219 for atopic dermatitis; SIT-052, an inhaled GLS1 inhibitor for pulmonary fibrosis and COPD that selectively breaks down senescent cells; SIT-033, a SIK2 inhibitor for ulcerative colitis; and SYX-1042 and SIT-047 for autoimmune indications (with Eli Lilly).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sitryx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cellenkos
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cellenkos
2.2 - Growth funds investing in similar companies to Cellenkos
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cellenkos
4.2 - Public trading comparable groups for Cellenkos
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →